Leukotriene B4 kit HTRF®

The Leukotriene B4 kit is designed for the accurate quantification of LTB4.
See more
  • Ready-to-use Ready-to-use
  • Highly specific Highly specific
  • Faster and more convenient than ELISA Faster and more convenient than ELISA
The Leukotriene B4 kit is designed for the accurate quantification of LTB4.
In stock


LTB4 is a major leukotriene product that is enzymatically derived from the arachidonic acid cascade. LTB4 is synthesized by leukocytes via the 5-lipoxygenase pathway and mediates different leukocyte functions such as lysosomal enzyme release, adhesion, and aggregation of polymorphonuclear leukocytes. LTB4 has been described as a potent mediator of inflammatory diseases and immunoregulation. The LTB4 kit enables the monitoring of LTB4 produced by cells and can be used to study the LTA4-hydrolase.



Assay principle

The LTB4 kit is a competitive immunoassay for the measurement of LTB4 in a range of biological formats. The assay uses an Eu3+-Cryptate conjugated antibody specific to LTB4 and XL665 coupled LTB4. LTB4 in the sample competes with XL665-labelled LTB4 for binding to anti-LTB4 Eu Cryptate.
LTB4 kit assay principle

Assay Protocol

The LTB4 assay features a streamlined protocol with only 1 incubation step after sample and LTB4 detection reagents dispensing. This protocol requires a single two-hour incubation period at RT.
LTB4 kit assay protocol

Key features

Incubation 1h at RT
Assay range 0.15 – 166.67 ng/mL
EC50 1.12 ng/mL
Detection limit 0.15 ng/mL
Specificity Low cross reactivity with 6-trans 12 epi LTB4
LTB4 standard curve

HTRF assays for Oncology and Inflammation

Signaling in the immune system - Brochures

Product Insert LTB4 Kit / 64LB4PEG-64LB4PEH

64LB4PEG-64LB4PEH - Product Insert

HTRF Product Catalog 2020 July update

All your HTRF assays in one document! - Catalog

A guide to Homogeneous Time Resolved Fluorescence

General principles of HTRF - Guides

How HTRF compares to Western Blot and ELISA

Get the brochure about technology comparison. - Brochures


Latest news